Directory → Immunotropona funds → Immunosuppressants → Simulect
This page is translated automatically with a help of Google Translate
SimulectSee also BasiliximabRoman nameSIMULECT, NOVARTIS PHARMA AGOf drugsImmunodepressant specific, receptor antagonist interleikina-2. Represents himernye monoclonal antibodies, the antibody properties mouse and human (IgG1k), which are directed against alfa-tsepi interleikina receptor-2 (CD25 antigen), expressiruemogo on the surface of lymphocytes in response to stimulation antigens. Simulect specifically binds to CD25 antigen on activated T-limfozitah, expressiruth vsokoaffinny interleikina receptor-2, and thus prevents binding interleikina-2 which is a signal for cell proliferation. Full and complete blockade interleikina receptor-2 maintained until baziliximaba concentration in the serum exceeds 0.2 g / J As reduce its level of expression CD25 antigen returned to the original values within 1-2 weeks. Simulect is a release or Cytokines mielosupression.ContraindicationsHypersensitivity to baziliximabu or other dairy products.OverdosingIn clinical studies Simulect put patients in a single dose of 60 mg or fractional doses to a total dose equivalent of 150 mg for 24 days, while there have been no serious adverse events.Storage conditionsThe temperature 2-8 ° CShelf life2The registration011528/01-1999 |
All products of this group |